Lapaquistat acetate, formerly known as TAK475, is a novel and potent squalene synthase inhibitor used as a cholesterol-lowering drug. As a squalene synthase inhibitor, Lapaquistat block the conversion of farnesyl diphosphate (FPP) to squalene. Lapaquistat acetate was originally designed for treating Mevalonate Kinase Deficiency (MKD), it is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage.

纯度：≥98%

CAS：189060-13-7